甲状腺癌组织中PLCD3和CCND1的表达及其临床意义-东南大学学报医学版

甲状腺癌组织中PLCD3和CCND1的表达及其临床意义

单位：唐山市人民医院头颈肝胆科, 河北唐山 063000

分类号：R736.1

出版年·卷·期（页码）：2025·44·第一期（46-52）

摘要：

目的:探究甲状腺癌(TC)组织中磷脂酶C δ3(PLCD3)和细胞周期蛋白D1(CCND1)的表达及其临床意义。方法:选择在本院2019年2月至2021年2月收治的126例TC患者为研究对象,收集患者术中切除的癌组织及其癌旁组织为组织样本。运用免疫组织化学法及实时荧光定量PCR检测TC组织中PLCD3、CCND1表达水平;分析TC组织中PLCD3、CCND1表达水平与临床病理特征及TC患者预后的相关性;采用多因素Cox回归分析影响TC患者预后的因素。结果:TC组织中PLCD3、CCND1的阳性表达率显著高于癌旁组织(P＜0.05),PLCD3、CCND1 mRNA表达水平也明显高于癌旁组织(P＜0.05)。临床分期为Ⅲ~Ⅳ期、有淋巴结转移及分化程度为低分化的TC患者PLCD3、CCND1阳性表达比例明显高于Ⅰ~Ⅱ期、无淋巴结转移及中高分化的TC患者(P＜0.05)。PLCD3阳性表达患者3年生存率(40/93,43.01%)低于PLCD3阴性表达患者(25/33,75.76%)(χ²=12.889,P<0.001);CCND1阳性表达患者3年生存率(41/96,42.71%)也低于CCND1阴性表达患者(24/30,80.00%)(χ²=13.939,P<0.001)。PLCD3、CCND1、临床分期、淋巴结转移是TC患者预后的影响因素(P＜0.05)。结论:TC组织PLCD3、CCND1阳性表达率显著升高,其与TC患者临床分期、淋巴结转移密切相关,对预测患者预后有一定参考价值。

Objective: To investigate the expression and clinical significance of phospholipase C-delta-3(PLCD3) and cyclin D1(CCND1) in thyroid cancer(TC) tissue. Methods:A total of 126 TC patients who were treated in our hospital from February 2019 to February 2021 were regarded as the study subjects, and the excised cancer tissue and its adjacent tissues during surgery were used as the controltissue samples. Immunohistochemical methods and real-time fluorescence quantitative PCR were applied to detect the expression levels of PLCD3 and CCND1 in TC tissues. The correlation between the expression levels of PLCD3 and CCND1 in TC tissue with clinical pathological characteristics and the prognosis of TC patients was analyzed. The factors affecting the prognosis of TC patients were analyzed using multivariate Cox regression. Results:The positive expression rates of PLCD3 and CCND1 in TC tissues were greatly higher than those in adjacent tissues(P<0.05). The expression levels of PLCD3 and CCND1 mRNA in TC tissues were significantly higher than those in paracancer tissues(P<0.05). The positive expression rates of PLCD3 and CCND1 in TC patients with clinical stages Ⅲ-Ⅳ, lymph node metastasis, and low differentiation were greatly higher than those in TC patients with clinical stages Ⅰ-Ⅱ, medium to high differentiation, and no lymph node metastasis(P<0.05). The 3-year survival rate of PLCD3 positive expression patients(40/93, 43.01%) was lower than that of PLCD3 negative expression patients(25/33, 75.76%)(χ²=12.889, P＜0.001). The 3-year survival rate of CCND1 positive expression patients(41/96, 42.71%) was lower than that of CCND1 negative expression patients(24/30, 80.00%)(χ²=13.939, P＜0.001). PLCD3, CCND1, clinical stage, and lymph node metastasis were prognostic factors for TC patients(P<0.05). Conclusion:The positive expression rates of PLCD3 and CCND1 in TC tissue are greatly increased, which is closely related to clinical staging and lymph node metastasis in TC patients, and has certain reference value for predicting prognosis.

参考文献：

[1] GRIMM D.Recent advances in thyroid cancer research[J]. Int J Mol Sci, 2022, 23(9):4631.
[2] BOUCAI L, ZAFEREO M, CABANILLAS M E.Thyroid cancer:a review[J]. JAMA, 2024, 331(5):425-435.
[3] 李宗禹, 徐金锴, 赖婧玥, 等.miR-93-5p靶向CCNG2基因对TC细胞增殖和凋亡的影响及其机制[J]. 现代肿瘤医学, 2020, 28(19):3325-3330.
[4] LIN L, WEN J, LIN B, et al.Phospholipase C delta 3 inhibits apoptosis and promotes proliferation, migration, and invasion of thyroid cancer cells via Hippo pathway[J]. Acta Biochim Biophys Sin(Shanghai), 2021, 53(4):481-491.
[5] ZHOU X, LIAO X, WANG X, et al.Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms[J]. Cancer Med, 2020, 9(3):859-871.
[6] SU Y, ZHOU H, MA Z, et al.CCND1-induced autophagy contributes to lymph node metastasis in endometrial cancer[J]. Horm Metab Res, 2023, 55(6):413-419.
[7] 中国抗癌协会妇科肿瘤专业委员会.TC诊断与治疗指南(第四版)[J]. 中国实用妇科与产科杂志, 2018, 34(6):613-622.
[8] 陈焱, 宋小平, 汤小虎, 等.C-met蛋白在肝癌组织中的表达及其与临床特征的关系[J]. 癌症进展, 2018, 16(4):472-474.
[9] QU N, HUI Z, SHEN Z, et al.Thyroid cancer and COVID-19:prospects for therapeutic approaches and drug development[J]. Front Endocrinol(Lausanne), 2022, 13(1):873027.
[10] 边芳, 李宁, 李奇.肽P11通过上调miR-126表达抑制分化型甲状腺癌细胞增殖和侵袭[J]. 现代医学, 2021, 49(8):833-840.
[11] ZHANG H, ZHAO Y C, WU Q, et al.The prognostic value of lymph node metastasis and the eighth edition of AJCC for patients with anaplastic thyroid cancer[J]. Clin Endocrinol(Oxf), 2021, 95(3):498-507.
[12] PRETE A, BORGES D E, SOUZA P, et al.Update on fundamental mechanisms of thyroid cancer[J]. Front Endocrinol(Lausanne), 2020, 11(1):102.
[13] WANG M, GAO M, CHEN Y, et al.PLCD3 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/P21 signaling[J]. BMC Cancer, 2023, 23(1):921.
[14] PAK O, ZAITSEV S, SHEVCHENKO V, et al.Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation[J]. Prog Brain Res, 2021, 266(1):195-209.
[15] DOU X L, XIA F D, LI X Y.Circ_0003747 promotes thyroid cancer progression by sponging miR-338-3p to upregulate PLCD3 expression[J]. Epigenetics, 2023, 18(1):2210339.
[16] VALLA M, KLÆSTAD E, YTTERHUS B, et al.CCND1 amplification in breast cancer-associations with proliferation, histopathological grade, molecular subtype and prognosis[J]. J Mammary Gland Biol Neoplasia, 2022, 27(1):67-77.
[17] NIE M, WANG Y, YU Z, et al.AURKB promotes gastric cancer progression via activation of CCND1 expression[J]. Aging(Albany NY), 2020, 12(2):1304-1321.
[18] LI X J, WEN R, WEN D Y, et al.Downregulation of miR193a3p via targeting cyclin D1 in thyroid cancer[J]. Mol Med Rep, 2020, 22(3):2199-2218.
[19] QIN Y.Identification of prognosis-associated biomarkers in thyroid carcinoma by a bioinformatics analysis[J]. Int J Gen Med, 2021, 14(1):5737-5747.
[20] 王思寅, 董颖, 滕立勤.TC组织中miR-93-5p、BRMS1L的表达水平及其临床意义[J]. 实用癌症杂志, 2023, 38(4):538-541.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录